Bristol-Myers Squibb Company (BMY) vs Vertex Pharmaceuticals Incorporated (VRTX)
A side-by-side comparison of Bristol-Myers Squibb Company and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 10, 2026. Differences are shown without an overall score or investment verdict.
BMY
Bristol-Myers Squibb Company
$63.64HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT
VRTX
Vertex Pharmaceuticals Incorporated
$515.44HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT
Total return — BMY vs VRTX
growth of $100 · dividends reinvested · last 10yBMY +68.1% (+5.3%/yr)VRTX +462.1% (+18.8%/yr)VRTX compounded faster over this window
BMY VRTX
BMY vs VRTX: by the numbers
- •VRTX is the larger company ($130.82B vs $130.00B market cap).
- •BMY trades at the lower trailing earnings multiple (14.02 vs 30.00 P/E), one valuation lens rather than an overall verdict.
- •VRTX converts more revenue to profit (34.89% vs 18.87% net margin).
- •VRTX grew revenue faster over the past five years (13.57% vs 2.08% CAGR).
- •BMY pays a dividend (3.94% yield), while VRTX has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | BMY | VRTX |
|---|---|---|
| P/E ratio | 14.02 | 30.00 |
| Forward P/E | 9.18 | 27.49 |
| P/S ratio | 2.64 | 10.36 |
| P/B ratio | 5.82 | 6.46 |
| EV / EBITDA | 9.71 | 24.88 |
| FCF yield | 8.80% | 2.90% |
Profitability
| Metric | BMY | VRTX |
|---|---|---|
| Gross margin | 70.16% | 86.04% |
| Operating margin | 28.27% | 38.59% |
| Net margin | 18.87% | 34.89% |
| ROE | 41.59% | 21.76% |
| ROIC | 15.47% | 17.33% |
Dividends
| Metric | BMY | VRTX |
|---|---|---|
| Dividend yield | 3.94% | N/A |
| Payout ratio | 55.29% | N/A |
Growth (annualized)
| Metric | BMY | VRTX |
|---|---|---|
| Revenue CAGR (5Y) | 2.08% | 13.57% |
| EPS CAGR (5Y) | 9.38% | 8.17% |
| FCF CAGR (5Y) | -0.95% | 16.39% |
| Total return CAGR (5Y) | 4.39% | 22.61% |
Frequently asked
- Which has the lower trailing P/E, BMY or VRTX?
- BMY has the lower trailing P/E: BMY trades at 14.02 and VRTX at 30.00. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BMY or VRTX?
- Over the past five years, VRTX grew revenue faster — BMY at a 2.08% CAGR versus VRTX at 13.57%.
- Does BMY or VRTX pay a bigger dividend?
- BMY pays a dividend (3.94% yield), while VRTX has no payments in the available dividend history.
- Is BMY or VRTX more profitable?
- VRTX runs the higher net margin — BMY at 18.87% versus VRTX at 34.89%.
- How have BMY and VRTX total returns compared?
- Over the past 10 years, BMY delivered 5.01% and VRTX delivered 18.72% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bristol-Myers Squibb P/E ratioVertex Pharmaceuticals P/E ratioBristol-Myers Squibb dividend yieldBristol-Myers Squibb ROEVertex Pharmaceuticals ROEBristol-Myers Squibb operating marginVertex Pharmaceuticals operating marginBristol-Myers Squibb revenue growthVertex Pharmaceuticals revenue growthBristol-Myers Squibb free cash flowVertex Pharmaceuticals free cash flow
Bristol-Myers Squibb & Vertex Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 10, 2026.